PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22994521-5	2012	Immnofluorescence and quantitative PCR studies showed that concurrent treatment with the ET-A/B receptor antagonist, bosentan (200 mg/kg/day), blocked CH-induced ED-1+ macrophage invasion and the upregulation of cytokines, including interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNFalpha), and monocyte chemoattractant protein-1 (MCP-1).	Bosentan	117-125	tumor necrosis factor	Rattus norvegicus	285-312	
27145076-9	2017	BOS regulates significantly eNOS, iNOS and TNF-alpha expressions in a dose-dependent manner.	Bosentan	0-3	tumor necrosis factor	Rattus norvegicus	43-52	
24918345-7	2015	Bosentan treatment showed a significant up-regulatory effect on ET-1, TNF-alpha and TGF-beta mRNA expression.	Bosentan	0-8	tumor necrosis factor	Rattus norvegicus	70-79	
22994521-5	2012	Immnofluorescence and quantitative PCR studies showed that concurrent treatment with the ET-A/B receptor antagonist, bosentan (200 mg/kg/day), blocked CH-induced ED-1+ macrophage invasion and the upregulation of cytokines, including interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNFalpha), and monocyte chemoattractant protein-1 (MCP-1).	Bosentan	117-125	tumor necrosis factor	Rattus norvegicus	314-322	
19897563-7	2010	Both BQ-123 and bosentan prevented the development of CSE-induced emphysema, blocked the expression of ET(A) receptor, inhibited pulmonary apoptosis, inactivated MMP-2 and MMP-9 activities in the lung tissues, reduced the concentrations of inflammatory cytokines TNF-alpha and IL-1beta, and improved the biological antioxidant activity in the serum.	Bosentan	16-24	tumor necrosis factor	Rattus norvegicus	263-272	
20646409-17	2010	BQ123 and bosentan significantly prevented the increases of the levels of TNFalpha and IL-1ss in lungs of rats with injection of CSE.	Bosentan	10-18	tumor necrosis factor	Rattus norvegicus	74-82